Assessing quality of life and survival in patients with rare cancers receiving targeted therapy
PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc
This study is trying to see if targeted therapies can improve the quality of life and survival for people with advanced rare cancers.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | British Columbia Cancer Agency Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Vancouver, British Columbia) |
| Trial ID | NCT04814095 on ClinicalTrials.gov |
What this trial studies
This pilot clinical trial evaluates the real-world quality of life and survival outcomes for patients with advanced rare cancers or those harboring rare molecular aberrations who are treated with targeted therapies approved by Health Canada. The study aims to generate real-world evidence to support health technology assessments, which are crucial for funding decisions. By focusing on patients who may not have access to nationally funded treatments, the trial seeks to address the uncertainties surrounding the effectiveness and quality of life impacts of these therapies. Participants will undergo assessments of their quality of life and receive CT imaging as part of the intervention.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with incurable malignancies identified as having rare cancers or molecular aberrations currently receiving Health Canada approved targeted therapy that is not nationally funded.
Not a fit: Patients who are currently participating in other clinical trials or those unable to complete quality of life assessments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide critical evidence to support funding and access to effective treatments for patients with rare cancers.
How similar studies have performed: While this approach is novel in its focus on rare cancers and real-world evidence, similar studies have shown promise in evaluating targeted therapies in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject age greater than or equal to 18 years at the time of signature of informed consent. * Subjects with an incurable malignancy who have been identified to have a rare cancer or rare molecular aberration who is currently receiving Health Canada approved targeted therapy that is not nationally funded * ECOG 0-2 * Life expectancy of at least 12 weeks * Adequate hematologic and end organ function for drug treatment per the clinician's assessment * Asymptomatic or treated brain metastases permitted * Ability to give informed consent for the study procedures defined in this protocol. Exclusion Criteria: * Treatment with any approved or investigational agent or participation in another clinical trial with therapeutic intent within 14 days prior to enrollment. * Inability to complete quality of life questionnaires * Subjects who are felt by the treating clinician to be unfit to proceed with this protocol.
Where this trial is running
Vancouver, British Columbia
- BC Cancer — Vancouver, British Columbia, Canada (Recruiting)
Study contacts
- Principal investigator: Cheryl Ho, MD — BC Cancer
- Study coordinator: Samantha Pollard, PhD
- Email: spollard@bccrc.ca
- Phone: 604-675-8000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.